Omega-3 Carboxylic Acids (Epanova®): A Review of Its Use in Patients with Severe Hypertriglyceridemia

@article{Blair2014Omega3CA,
  title={Omega-3 Carboxylic Acids (Epanova{\textregistered}): A Review of Its Use in Patients with Severe Hypertriglyceridemia},
  author={Hannah A. Blair and Sohita Dhillon},
  journal={American Journal of Cardiovascular Drugs},
  year={2014},
  volume={14},
  pages={393-400}
}
Omega-3 carboxylic acids (Epanova®) [OM3-CA] is the first free fatty acid form of long-chain marine omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid being the most abundant) to be approved by the US FDA as an adjunct to diet to lower triglyceride levels in patients with severe hypertriglyceridemia (≥500 mg/dL). Oral OM3-CA has greater bioavailability than ethyl ester forms of omega-3 and, unlike omega-3 acid ethyl esters, does not require co-ingestion of a high-fat meal, as… Expand
Do we need ‘new’ omega-3 polyunsaturated fatty acids formulations?
TLDR
There is the need to understand if long-term PUFA supplementation could increase the efficacy of the already-available evidence–based therapies for cardiovascular disease prevention and for the management of the diseases where the use of PUFA could have a possible improving effect. Expand
The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia.
TLDR
Reduction in apoCIII may be a mechanism for the TG-lowering effects of OM3-CA and the increase in LDL-C seen in the EVOLVE trial may not be associated with increased risk of CVD. Expand
Omega-3 polyunsaturated fatty acids: anti-inflammatory and anti-hypertriglyceridemia mechanisms in cardiovascular disease
TLDR
The evidence shows that Ω-3 fatty acids have a beneficial effect on CVD through reprogramming of TRL metabolism, reducing inflammatory mediators (cytokines and leukotrienes), and modulation of cell adhesion molecules. Expand
Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia
TLDR
Icosabutate was efficacious in lowering non-HDL-C and other biomarkers of cardiovascular risk and was generally well tolerated in patients with persistent hypertriglyceridemia despite statin therapy. Expand
Effects of Food on the Pharmacokinetics of Omega-3-Carboxylic Acids in Healthy Japanese Male Subjects: A Phase I, Randomized, Open-label, Three-period, Crossover Trial
TLDR
The timing of OM3-CA administration relative to food intake influences the systemic bioavailability of EPA and DHA in healthy Japanese male subjects. Expand
Recent developments in pharmacotherapy for hypertriglyceridemia: what’s the current state of the art?
TLDR
This review presents the most recent advances in hypertriglyceridemia treatment and critically comments on apolipoprotein C-III inhibitors, angiopoietin-like 3 inhibitors, alipogene tiparvovec, pradigastat, pemafibrate and novel formulations of omega-3 fatty acids. Expand
Role of Omega-3 Fatty Acids in Metabolic Syndrome
TLDR
This chapter will focus on reviewing randomized, controlled trials that evaluate the effects of supplementation with marine-derived EPA and DHA on weight loss, insulin sensitivity, lipid metabolism, blood pressure, and inflammation in overweight/obese subjects with MetS characteristics. Expand
Fatty Acids Consumption: The Role Metabolic Aspects Involved in Obesity and Its Associated Disorders
TLDR
This current review shows that the consumption of unsaturated fatty acids, MUFA, and PUFA; and especially EPA and DHA, which can be applied as food supplements, may promote effects on glucose and lipid metabolism, as well as on metabolic inflammation, gut microbiota, and hepatic metabolism. Expand
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of an Omega‐3‐Carboxylic Acid Formulation in Healthy Male Japanese Subjects: A Phase 1 Single‐Blind, Randomized, Placebo‐Controlled Trial
TLDR
Overall, OM3‐CA was well tolerated in healthy Japanese subjects and the pharmacokinetic profiles of EPA and DHA after administration of OM3-CA were comparable between Japanese and white subjects. Expand
Nutrigenomics of ω-3 fatty acids: Regulators of the master transcription factors.
TLDR
Some aspects of ω-3 LC-PUFAs are described-from their structural function in cell membranes to their role as regulators of gene expression, mainly in lipid metabolism, as well as their functions as nutrients with protective action to avoid or delay development of these diseases. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 20 REFERENCES
Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial.
TLDR
OM3-FFA achieved the primary end point for TG lowering and secondary end point of non-HDL-C lowering at 2, 3, and 4 g/d in persons with severe hypertriglyceridemia in a multinational, double-blind, randomized, out-patient study. Expand
Overview of omega-3 Fatty Acid therapies.
TLDR
The REDUCE-IT study is being conducted to evaluate the effect of the combination of IPE and statins on cardiovascular outcomes in high-risk patients. Expand
Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia
TLDR
P-OM3 are effective in reducing triglycerides by ∼ 30% in this population and are likely to be combined with other drugs (e.g., statins) to treat combined dyslipidemia. Expand
Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options.
TLDR
There remains a need for further cardiovascular outcomes studies for adjunct therapy and the potential place for omega-3 fatty acids as such in statin-treated patients. Expand
Management of Severe Hypertriglyceridemia with a Novel Omega-3 Free- Fatty Acid Formulation: Subgroups in the EVOLVE Trial
TLDR
The effects of IPE in the ANCHOR study on the exploratory endpoints of lipoprotein particle concentration; the correlation with ApoB; and the fatty acid desaturation index (FADI), a biomarker of hepatic stearoylCoA desaturase (SCD) activity, were found to significantly reduce median TG and apolipoprotein B. Expand
A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).
TLDR
OM3-FFA was well tolerated and lowered non-HDL-C and TG levels at both 2- and 4-g/d dosages in patients with persistent hypertriglyceridemia taking a statin, with the 4-G/d dosage providing incremental improvements compared with 2 g/d. Expand
Epanova(®) and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy.
TLDR
Epanova is a novel ω-3 free fatty acid formulation, developed to maximize eicosapentenoic acid and docosahexenoic acids bioavailability with low-fat diets, suggesting a potential therapeutic advantage compared with ω -3-acid ethyl esters in the treatment of patients with hypertriglyceridemia. Expand
A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study.
TLDR
During a low-fat consumption period, the OM-3 FFA formulation provided dramatically improved bioavailability over the OM (OM-3 EE) formulation in overweight subjects, offering a potential therapeutic advantage of the OM -3 F FA formulation for the treatment of severe hypertriglyceridemia. Expand
Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids.
  • M. Davidson
  • Medicine
  • The American journal of cardiology
  • 2006
TLDR
Omega-3 fatty acids are more potent hypotriglyceridemic agents than are omega-6 fatty acids, on a carbon-for-carbon basis. Expand
Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study
TLDR
The bioavailability of the FFA forms of EPA and DHA in Epanova are significantly greater than the bioavailability from the EE forms present in Lovaza under low-fat dietary conditions normally recommended for patients with cardiovascular disease, and may lead to improved triglyceride-lowering in patients with hypertriglyceridemia. Expand
...
1
2
...